RxDoctor Payments Data

Samuel Kingsley, NP

Psychiatric/Mental Health · Scarborough, MENPI 1558935338

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 303 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 32.1% of the total. 2025 is the largest year on record at $2,326, 7.7 times the $302 reported in 2021. Among psychiatric/mental health clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,847in general payments, 2019–2025

Across 303 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$2K
  • AbbVie$902
  • Alkermes, Inc.$690
  • Axsome Therapeutics, Inc.$559
  • Otsuka America Pharmaceutical, Inc.$443
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$363
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$5,830100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,847 in reported general payments places this provider in the 95th percentile of 192 psychiatric/mental health providers in Maine.

See all psychiatric/mental health providers in Maine

Medicare billing

Part B allowed, 2024
$5,489
Medicare patients
18
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate16$57,475
Duloxetine Hcl21$2,951
Aripiprazole11$2,747
Fluoxetine Hcl59$2,310
Lurasidone Hcl11$2,205
Risperidone OdtRisperidone12$938
Clozapine36$824
Divalproex Sodium ErDivalproex Sodium15$765
Olanzapine25$688
Methylphenidate ErMethylphenidate Hcl16$621
Guanfacine Hcl ErGuanfacine Hcl21$583
Clonazepam29$556
Quetiapine Fumarate17$548
Risperidone38$486
Sertraline Hcl35$429

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Scarborough

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →